Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 4/20 | 0.53 |
| ▸ | ITGA4 | P13612 | 3/20 | 0.53 |
| ▸ | ITGB3 | P05106 | 6/20 | 0.51 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.51 |
| ▸ | PPARG | P37231 | 5/20 | 0.49 |
| ▸ | PPARA | Q07869 | 3/20 | 0.49 |
| ▸ | PPARD | Q03181 | 1/20 | 0.49 |
| ▸ | ACACB | O00763 | 1/20 | 0.48 |
| ▸ | TPH1 | P17752 | 2/20 | 0.47 |
| ▸ | ITGAV | P06756 | 1/20 | 0.45 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.44 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.44 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15037029 | 1.00 | ITGB1 (0.53) | ITGB1ITGA4ITGB3ITGA2BPPARG | |
| SCHEMBL15019772 | 1.00 | ITGB1 (0.53) | ITGB1ITGA4ITGB3ITGA2BPPARG | |
| SCHEMBL15091874 | 1.00 | ITGB1 (0.53) | ITGB1ITGA4ITGB3ITGA2BPPARG | |
| SCHEMBL15037257 | 0.94 | PPARG (0.51) | ITGB1ITGA4ITGB3ITGA2BPPARG | |
| SCHEMBL22449060 | 0.94 | PPARG (0.51) | ITGB1ITGA4ITGB3ITGA2BPPARG | |
| SCHEMBL17834375 | 0.94 | ITGB1 (0.51) | ITGB1ITGA4ITGB3ITGA2BPPARG | |
| SCHEMBL15037027 | 0.93 | RAB9A (0.48) | ITGB1ITGA4ITGB3ITGA2BPPARG | |
| SCHEMBL15019927 | 0.93 | RAB9A (0.48) | ITGB1ITGA4ITGB3ITGA2BPPARG | |
| SCHEMBL15019925 | 0.93 | RAB9A (0.48) | ITGB1ITGA4ITGB3ITGA2BPPARG | |
| SCHEMBL15091930 | 0.93 | RAB9A (0.48) | ITGB1ITGA4ITGB3ITGA2BPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3008056-B1 | NOVEL GLP-1 RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2020-12-09 | — | — | EP | disclosed |
| EP-3008056-B1 | NOVEL GLP-1 RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2020-12-09 | — | — | EP | disclosed |
| EP-2791112-B1 | CARBOXYLIC ACID DERIVATIVES COMPRISING FOUR CYCLES ACTING AS GLP-1 RECEPTOR MODULATORS FOR THERAPY OF DISEASES SUCH AS DIABETES | CELGENE INT II SÀRL (CH) | 2020-09-23 | — | — | EP | disclosed |
| EP-2791112-B1 | CARBOXYLIC ACID DERIVATIVES COMPRISING FOUR CYCLES ACTING AS GLP-1 RECEPTOR MODULATORS FOR THERAPY OF DISEASES SUCH AS DIABETES | CELGENE INT II SÀRL (CH) | 2020-09-23 | — | — | EP | disclosed |
| EP-3230276-B1 | GLP-1 RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2020-09-02 | — | — | EP | disclosed |
| US-10259823-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2019-04-16 | — | — | US | disclosed |
| US-10259823-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2019-04-16 | — | — | US | disclosed |
| US-10034886-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2018-07-31 | — | — | US | disclosed |
| US-10034886-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2018-07-31 | — | — | US | disclosed |
| US-10034886-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2018-07-31 | — | — | US | disclosed |
| US-20150011527-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2015-01-08 | — | — | US | disclosed |
| US-20150011527-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2015-01-08 | — | — | US | disclosed |
| WO-2014201172-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS, INC. (US) | 2014-12-18 | — | — | WO | disclosed |
| US-8778923-B2 | GLP-1 receptor modulators | RECEPTOS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-8778923-B2 | GLP-1 receptor modulators | RECEPTOS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-8778923-B2 | GLP-1 receptor modulators | RECEPTOS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20130178420-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130178420-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130178420-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| WO-2013090454-A2 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS, INC. (US) | 2013-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178420-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | ITGB1 3770/4885ITGA4 4634/4885ITGB3 4076/4885 |
| US-10034886-B2 | GLP-1 receptor modulators | GLP1R, GIPR, GCGR | ITGB1 3369/4885ITGA4 4604/4885ITGB3 3678/4885 |
| US-10259823-B2 | GLP-1 receptor modulators | GLP1R, GIPR, GCGR | ITGB1 3369/4885ITGA4 4604/4885ITGB3 3678/4885 |
| US-20150011527-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | ITGB1 3589/4885ITGA4 4651/4885ITGB3 4025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.